| Literature DB >> 34855607 |
Morena Danieli1, Seyed Mahed Mousavi1, Giuseppe Riccardi1, Tommaso Ciulli2.
Abstract
BACKGROUND: Mobile apps for mental health are available on the market. Although they seem to be promising for improving the accessibility of mental health care, little is known about their acceptance, design methodology, evaluation, and integration into psychotherapy protocols. This makes it difficult for health care professionals to judge whether these apps may help them and their patients.Entities:
Keywords: conversational AI; mHealth; mental health care; participatory design; personal health care agents; psychotherapy
Year: 2021 PMID: 34855607 PMCID: PMC8686486 DOI: 10.2196/30053
Source DB: PubMed Journal: JMIR Form Res ISSN: 2561-326X
Figure 1The information flow in the proposed approach. The patients interact with the mobile personal health care agent (m-PHA) to share personal recollections of their life events. The therapists supervise the interaction of the m-PHA with the patients and elaborate on the patients’ personal narratives during the therapy session. ABC: antecedents, beliefs, and consequences; m-PHA: mobile personal health care agent.
Figure 2The CONSORT (Consolidated Standards of Reporting Trials) diagram shows the flow of the intervention, the enrollment of participants, their allocation to treatment, follow-up, and analysis. CBT: cognitive behavioral therapy; m-PHA: mobile personal health care agent; SMT: stress management training; T3: assessment of psychopathological outcomes 3 months after treatment.
Sample characteristics (N=21).
| Characteristic | Values | |
| Age (years), mean (SD) | 47.76 (8.07) | |
|
| ||
|
| Male | 4 (19) |
|
| Female | 17 (81) |
|
| ||
|
| Group A | 11 (52) |
|
| Group B | 10 (48) |
|
| ||
|
| High school | 7 (33) |
|
| Degree | 10 (48) |
|
| Master’s degree or PhDa | 4 (19) |
|
| ||
|
| Single | 3 (14) |
|
| Cohabiting | 4 (19) |
|
| Married | 13 (62) |
|
| Separated | 1 (5) |
aPhD: Doctor of Philosophy.
Parametric analysis of differences between group A (n=11) and group B (n=10) at baseline (T1), after 8 weeks of treatment (T2), and 3 months after treatment (T3): Perceived Stress Scale (PSS) and Symptom Checklist-90-Revised tests.
| Scale | Group A, mean (SD) | Group B, mean (SD) | |||||||
|
| |||||||||
|
| T1 | 22.09 (2.21) | 20.40 (6.83) | 0.75 (10.7) | .47 | ||||
|
| T2 | 16.55 (5.45) | 14.80 (5.45) | 0.73 (19) | .47 | ||||
|
| T3 | 18 (7.32) | 10.29 (6.63) | 2.22 (15) | .04 | ||||
|
| |||||||||
|
| T1 | 60.36 (6.82) | 55.70 (7.92) | 1.45 (19) | .16 | ||||
|
| T2 | 55.82 (6.82) | 49.00 (8.60) | 2.02 (19) | .06 | ||||
|
| T3 | 53.89 (8.71) | 47.00 (6.13) | 1.67 (13) | .12 | ||||
|
| |||||||||
|
| T1 | 62.82 (6.81) | 58.20 (9.66) | 1.28 (19) | .22 | ||||
|
| T2 | 60.73 (10.38) | 51.00 (12.13) | 1.98 (19) | .06 | ||||
|
| T3 | 57.00 (8.02) | 48.83 (7.76) | 1.96 (13) | .07 | ||||
|
| |||||||||
|
| T1 | 53.82 (5.64) | 51.00 (8.01) | 0.94 (19) | .36 | ||||
|
| T2 | 48.91 (4.57) | 47.80 (5.31) | 0.51 (19) | .61 | ||||
|
| T3 | 49.00 (6.04) | 45.17 (4.21) | 1.34 (13) | .20 | ||||
|
| |||||||||
|
| T1 | 52.64 (7.45) | 50.40 (8.51) | 0.64 (19) | .53 | ||||
|
| T2 | 49.64 (6.45) | 47.50 (9.19) | 0.62 (19) | .54 | ||||
|
| T3 | 48.78 (7.17) | 46.17 (9.56) | 0.61 (13) | .56 | ||||
|
| |||||||||
|
| T1 | 62.55 (8.95) | 51.30 (7.63) | 3.08 (19) | .006 | ||||
|
| T2 | 56.55 (8.78) | 48.20 (9.78) | 2.06 (19) | .05 | ||||
|
| T3 | 55.11 (8.04) | 48.17 (7.52) | 1.68 (13) | .12 | ||||
|
| |||||||||
|
| T1 | 63.27 (8.86) | 57.80 (8.59) | 1.43 (19) | .17 | ||||
|
| T2 | 57.36 (9.29) | 51.70 (8.41) | 1.46 (19) | .16 | ||||
|
| T3 | 57.44 (11.90) | 47.33 (6.83) | 1.87 (13) | .08 | ||||
|
| |||||||||
|
| T1 | 57.55 (10.21) | 56.50 (9.17) | 0.25 (19) | .81 | ||||
|
| T2 | 59.27 (9.09) | 49.60 (6.15) | 2.82 (19) | .01 | ||||
|
| T3 | 53.00 (6.67) | 48.33 (3.50) | 1.56 (13) | .14 | ||||
aGSI: Global Severity Index.
bPST: Positive Symptom Total.
cPSDI: Positive Symptom Distress Index.
Parametric analysis of differences between group A (n=11) and group B (n=10) at baseline (T1), after 8 weeks of treatment (T2), and 3 months after treatment (T3): Occupational Stress Indicator test.
| Scale | Group A, mean (SD) | Group B, mean (SD) | |||||||
|
| |||||||||
|
| T1 | 5.91 (1.51) | 5.90 (0.99) | 0.02 (19) | .99 | ||||
|
| T2 | 6.36 (2.16) | 5.50 (1.35) | 1.08 (19) | .29 | ||||
|
| T3 | 5.90 (2.18) | 7.33 (1.03) | –1.77 (13.6) | .10 | ||||
|
| |||||||||
|
| T1 | 5.45 (1.51) | 4.90 (1.37) | 0.88 (19) | .39 | ||||
|
| T2 | 5.82 (1.33) | 6.10 (1.97) | –0.39 (19) | .70 | ||||
|
| T3 | 5.30 (1.25) | 7.50 (1.05) | –3.60 (14) | .003 | ||||
|
| |||||||||
|
| T1 | 5.36 (1.96) | 4.80 (1.99) | 0.65 (19) | .52 | ||||
|
| T2 | 5.55 (0.93) | 5.90 (1.52) | –0.65 (19) | .52 | ||||
|
| T3 | 5.50 (1.58) | 5.67 (1.37) | –0.21 (14) | .83 | ||||
|
| |||||||||
|
| T1 | 5.45 (2.16) | 6.10 (1.79) | –0.74 (19) | .47 | ||||
|
| T2 | 5.64 (1.96) | 6.20 (1.32) | –0.76 (19) | .45 | ||||
|
| T3 | 6.10 (1.45) | 6.83 (1.17) | –1.05 (14) | .31 | ||||
|
| |||||||||
|
| T1 | 5.00 (1.34) | 5.20 (1.99) | –0.27 (19) | .79 | ||||
|
| T2 | 5.09 (1.87) | 5.80 (1.32) | –0.99 (19) | .33 | ||||
|
| T3 | 5.10 (2.18) | 6.50 (2.07) | –1.26 (14) | .23 | ||||
|
| |||||||||
|
| T1 | 5.73 (1.95) | 5.90 (1.10) | –0.25 (19) | .81 | ||||
|
| T2 | 5.82 (1.08) | 5.60 (1.84) | 0.34 (19) | .74 | ||||
|
| T3 | 6.00 (1.25) | 7.67 (1.37) | –2.5 (14) | .03 | ||||
Nonparametric analysis of differences between group A (n=11) and group B (n=10) at baseline (T1), after 8 weeks of treatment (T2), and 3 months after treatment (T3): Perceived Stress Scale (PSS) and Symptom Checklist-90-Revised tests.
| Scale | Group A | Group B | Z value | ||||||||||||||||||||||
|
| Mean (SD) | Median | Mean rank | Mean (SD) | Median | Mean rank |
|
|
| ||||||||||||||||
|
| |||||||||||||||||||||||||
|
| T1 | 22.09 (2.21) | 23.00 | 11.50 | 20.40 (6.83) | 21.00 | 10.45 | 49.50 | –0.39 | .72 | |||||||||||||||
|
| T2 | 16.55 (5.45) | 17.00 | 11.73 | 14.80 (5.45) | 15.00 | 10.20 | 47.00 | –0.56 | .59 | |||||||||||||||
|
| T3 | 18 (7.32) | 18.50 | 11.15 | 10.29 (6.63) | 13.00 | 5.93 | 13.05 | –2.10 | .03 | |||||||||||||||
|
| |||||||||||||||||||||||||
|
| T1 | 60.36 (6.82) | 62.00 | 12.82 | 55.70 (7.92) | 58.00 | 9.00 | 35.00 | –1.41 | .17 | |||||||||||||||
|
| T2 | 55.82 (6.82) | 58.00 | 13.59 | 49.00 (8.60) | 49.00 | 8.15 | 26.50 | –2.01 | .04 | |||||||||||||||
|
| T3 | 53.89 (8.71) | 52.00 | 9.67 | 47.00 (6.13) | 45.00 | 5.50 | 12.00 | –1.77 | .09 | |||||||||||||||
|
| |||||||||||||||||||||||||
|
| T1 | 62.82 (6.81) | 63.00 | 12.45 | 58.20 (9.66) | 59.50 | 9.40 | 39.00 | –1.13 | .28 | |||||||||||||||
|
| T2 | 60.73 (10.38) | 62.00 | 13.55 | 51.00 (12.13) | 50.50 | 8.20 | 27.00 | –1.98 | .05 | |||||||||||||||
|
| T3 | 57.00 (8.02) | 58.00 | 9.67 | 48.83 (7.76) | 44.00 | 5.50 | 12.00 | –1.77 | .08 | |||||||||||||||
|
| |||||||||||||||||||||||||
|
| T1 | 62.55 (8.95) | 63.00 | 13.95 | 51.30 (7.63) | 53.00 | 7.75 | 22.50 | –2.30 | .02 | |||||||||||||||
|
| T2 | 56.55 (8.78) | 56.00 | 13.68 | 48.20 (9.78) | 47.00 | 8.05 | 25.5 | –2.08 | .04 | |||||||||||||||
|
| T3 | 55.11 (8.04) | 54.00 | 9.50 | 48.17 (7.52) | 46.00 | 5.75 | 13.50 | –1.60 | .13 | |||||||||||||||
|
| |||||||||||||||||||||||||
|
| T1 | 63.27 (8.86) | 64.00 | 12.73 | 57.80 (8.59) | 59.00 | 9.10 | 36.00 | –1.34 | .19 | |||||||||||||||
|
| T2 | 57.36 (9.29) | 57.00 | 12.68 | 51.70 (8.41) | 48.50 | 9.15 | 36.50 | –1.31 | .20 | |||||||||||||||
|
| T3 | 57.44 (11.90) | 55.00 | 9.94 | 47.33 (6.83) | 44.50 | 5.08 | 9.50 | –2.07 | .04 | |||||||||||||||
|
| |||||||||||||||||||||||||
|
| T1 | 57.55 (10.21) | 54.00 | 10.82 | 56.50 (9.17) | 56.00 | 11.20 | 53.00 | –0.14 | .90 | |||||||||||||||
|
| T2 | 59.27 (9.09) | 62.00 | 14.18 | 49.60 (6.15) | 49.00 | 7.50 | 20.00 | –2.48 | .01 | |||||||||||||||
|
| T3 | 53.00 (6.67) | 53.00 | 9.39 | 48.33 (3.50) | 47.00 | 5.92 | 14.50 | –1.48 | .15 | |||||||||||||||
aGSI: Global Severity Index.
bPST: Positive Symptom Total.
Nonparametric analysis of differences between group A (n=11) and group B (n=10) at baseline (T1), after 8 weeks of treatment (T2), and 3 months after treatment (T3): Occupational Stress Indicator test.
| Scale | Group A | Group B | Z value | |||||||||||
|
| Mean (SD) | Median | Mean rank | Mean (SD) | Median | Mean rank |
|
|
| |||||
|
| ||||||||||||||
|
| T1 | 5.91 (1.51) | 6.00 | 11.05 | 5.90 (0.99) | 6.00 | 10.95 | 54.5 | –0.04 | .99 | ||||
|
| T2 | 6.36 (2.16) | 7.00 | 12.95 | 5.50 (1.35) | 6.00 | 8.85 | 33.50 | –1.56 | .13 | ||||
|
| T3 | 5.90 (2.18) | 6.5 | 7.60 | 7.33 (1.03) | 7.00 | 10.00 | 21.00 | –1.00 | .32 | ||||
|
| ||||||||||||||
|
| T1 | 5.45 (1.51) | 5.00 | 12.05 | 4.90 (1.37) | 5.00 | 9.85 | 43.5 | –0.84 | .44 | ||||
|
| T2 | 5.82 (1.33) | 6.00 | 10.14 | 6.10 (1.97) | 6.00 | 11.95 | 45.50 | –0.68 | .53 | ||||
|
| T3 | 5.30 (1.25) | 6.00 | 5.95 | 7.50 (1.05) | 7.00 | 12.75 | 4.50 | –2.85 | .004 | ||||
|
| ||||||||||||||
|
| T1 | 5.36 (1.96) | 6.00 | 11.91 | 4.80 (1.99) | 5.00 | 10.00 | 45.00 | –0.73 | .49 | ||||
|
| T2 | 5.55 (0.93) | 5.00 | 10.09 | 5.90 (1.52) | 6.00 | 12.00 | 45.00 | –0.73 | .5 | ||||
|
| T3 | 5.50 (1.58) | 5.5 | 8.30 | 5.67 (1.37) | 6.00 | 8.83 | 28.00 | –0.22 | .85 | ||||
|
| ||||||||||||||
|
| T1 | 5.45 (2.16) | 5.00 | 10.05 | 6.10 (1.79) | 6.00 | 12.05 | 44.5 | –0.75 | .46 | ||||
|
| T2 | 5.64 (1.96) | 6.00 | 10.27 | 6.20 (1.32) | 7.00 | 11.80 | 47.00 | –0.58 | .58 | ||||
|
| T3 | 6.10 (1.45) | 6.00 | 7.60 | 6.83 (1.17) | 7.00 | 10.00 | 21.00 | –1.00 | .35 | ||||
|
| ||||||||||||||
|
| T1 | 5.00 (1.34) | 6.00 | 10.86 | 5.20 (1.99) | 5.00 | 11.15 | 53.5 | –0.11 | .95 | ||||
|
| T2 | 5.09 (1.87) | 6.00 | 9.50 | 5.80 (1.32) | 6.00 | 12.65 | 38.50 | –1.23 | .22 | ||||
|
| T3 | 5.10 (2.18) | 5.00 | 7.40 | 6.50 (2.07) | 6.50 | 10.33 | 19.00 | –1.22 | .23 | ||||
|
| ||||||||||||||
|
| T1 | 5.73 (1.95) | 6.00 | 10.23 | 5.90 (1.10) | 6.00 | 11.85 | 46.5 | –0.63 | .56 | ||||
|
| T2 | 5.82 (1.08) | 6.00 | 11.09 | 5.60 (1.84) | 6.00 | 10.90 | 54.00 | –0.07 | .95 | ||||
|
| T3 | 6.00 (1.25) | 6.00 | 6.55 | 7.67 (1.37) | 7.50 | 11.75 | 10.50 | –2.19 | .03 | ||||